Sanofi acquires over-the-counter rights for Cialis

by The Associated Press
Viagra pill

French drugmaker Sanofi is buying the rights to seek approval for a version of the erectile dysfunction drug Cialis that customers would be able to buy without a doctor's prescription.

Sanofi will acquire the rights from its U.S. counterpart Eli Lilly and Co. for the United States, Europe, Canada and Australia under the deal.

Lilly spokeswoman Celeste Stanley says they don't expect to launch such a version before 2018.

Cialis is currently sold only through prescription. It brought in $2.16 billion in last year, but it will lose patent protection in the U.S. and other markets in 2017. That will expose the drug to competition from cheaper, .

Terms of the Sanofi-Lilly deal were not disclosed.

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Eli Lilly to buy part of Novartis for $5.4 bn

Apr 22, 2014

US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

FDA approves first generic versions of Cymbalta

Dec 11, 2013

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments